GHRP-6 vs Ipamorelin: Comparing Two GH Secretagogues

Crown Peptides supplies research compounds for laboratory use only. Our products are not intended for human consumption and are not sold, marketed or labelled for the diagnosis, treatment, cure or prevention of any disease.

Ask the same receptor to do one job and you might get one clean answer. Ask it to do that job while also nudging three other hormone systems along for the ride, and you get GHRP-6. That is the whole tension at the centre of this comparison: two peptides that both trigger the ghrelin receptor to release growth hormone, but only one of them does it without waking up the rest of the endocrine system in the process.

GHRP-6 came first, discovered in the 1980s as one of the original growth hormone-releasing peptides. Ipamorelin arrived roughly a decade later, engineered specifically to fix what researchers saw as GHRP-6’s biggest limitation. Understanding that limitation — and how Ipamorelin was built to avoid it — is most of what you need to know to choose between them.

• Both peptides activate the ghrelin receptor (GHS-R1a) to stimulate growth hormone release from the pituitary.
• GHRP-6 also raises ACTH, cortisol, and prolactin alongside GH, and reliably increases appetite — an effect documented across multiple species.
• Ipamorelin was the first growth hormone secretagogue shown in published research to trigger GH release with minimal effect on those other hormone axes.
• GHRP-6’s GH-releasing effect depends partly on the body’s own GHRH signalling being intact, according to receptor-blockade research.
• Neither compound is approved for human use in the UK — both are supplied by Crown Peptides strictly for laboratory research.

Where the GHRP Family Actually Came From

GHRP-6 traces back to research in the early-to-mid 1980s screening synthetic opioid-related peptide fragments for unexpected hormonal activity — work that unexpectedly turned up small peptides capable of triggering growth hormone release through a mechanism that had nothing to do with GHRH. That was a genuinely surprising finding at the time, because it implied the existence of an entirely separate GH-regulating receptor the field did not yet know about. It would take until the late 1990s for that receptor to be formally identified as GHS-R1a — the same receptor later confirmed as the natural target of ghrelin, the hormone secreted by the stomach that drives hunger. GHRP-6 had been quietly activating the ghrelin pathway more than a decade before ghrelin itself was even discovered.

Ipamorelin arrived in 1998 as part of a deliberate second generation of research on that same receptor family, once the earlier compounds’ broader hormonal effects were well documented and pharmaceutical researchers began asking whether a cleaner, more selective version was possible.

Both GHRP-6 and Ipamorelin are hexapeptides, and both work on the same ghrelin receptor (GHS-R1a) in the pituitary and hypothalamus that the natural hunger hormone ghrelin also activates. That shared mechanism is exactly why they get compared so often — and exactly why the differences between them matter so much once you look past the headline similarity.

The original GHRP-6 synergy work, published back in 1989, showed that combining GHRP-6 with GHRH produced a growth hormone response larger than either compound alone — an early clue that these peptides were tapping into a genuinely separate pathway from GHRH itself, not just duplicating it (Bowers et al., 1989). Later receptor-blockade research went further, finding that GHRP-6 actually requires intact endogenous GHRH signalling to produce its maximal effect — the two pathways turned out to be more intertwined than the original synergy data alone suggested (Pandya et al., 1998).

GHRP-6’s Trade-Off: Power That Comes With Passengers

Here is the part researchers run into quickly with GHRP-6: it does not stimulate GH release in isolation. Because it activates the same ghrelin receptor pathway that governs hunger, GHRP-6 reliably increases appetite — an effect so consistent it shows up even in fish. A study in goldfish found GHRP-6 mimicked ghrelin’s dual effect of stimulating food intake and suppressing locomotor activity, evidence that this appetite pathway is deeply conserved across vertebrate biology rather than a quirk of one species or one receptor subtype (Matsuda et al., 2012).

GHRP-6 also does not confine itself to the GH axis. Comparative research measuring GHRP-6 alongside ghrelin and GHRH found it raised ACTH and cortisol as well as GH — a broader hormonal footprint than researchers modelling an isolated GH pathway usually want (Arwert et al., 2005). None of this makes GHRP-6 a poorly designed molecule — it was one of the first tools of its kind, built before selectivity was even a design goal — but it does mean any protocol using it needs to account for appetite and stress-axis activity as genuine variables, not noise to be ignored.

Ipamorelin’s Answer: Selectivity by Design

Ipamorelin exists because researchers wanted a version of the same GH-releasing effect without the passengers. The landmark 1998 paper that introduced it is literally titled “the first selective growth hormone secretagogue” — and the data backs the name. Across the reported dose range, Ipamorelin released GH as potently as GHRP-6 while producing minimal measurable change in ACTH, cortisol, aldosterone, or prolactin (Raun et al., 1998).

That selectivity comes down to a small but consequential structural change. Ipamorelin swaps two of GHRP-6’s amino acids for an Aib (2-aminoisobutyric acid) residue and a naphthylalanine residue — a redesign that keeps the peptide’s grip on the ghrelin receptor’s GH-releasing conformation while loosening whatever structural feature let GHRP-6 spill over into the ACTH and cortisol pathways. Follow-up work examining whether GH-releasing peptides act as true ghrelin secretagogues more broadly continued to support Ipamorelin’s cleaner mechanistic profile relative to earlier compounds in the class (Bowers, 2001).

Choosing Between Them for a Study Design

If a research question is specifically about the appetite-hunger axis, or about how GH and cortisol pathways interact when both are activated together, GHRP-6’s broader hormonal footprint is a feature, not a bug — it is a more complete model of ghrelin-receptor activation as it plays out across multiple systems at once.

If the research question is narrowly about the GH/IGF-1 axis and a confound from cortisol, ACTH, or appetite effects would muddy the data, Ipamorelin’s selectivity is the more useful tool — that is precisely the gap it was engineered to close.

Both peptides are short enough, and stable enough once lyophilised, that dosing frequency is less of a differentiator between them than it is for longer GHRH analogs — the practical decision usually comes down to hormonal selectivity rather than pharmacokinetics. Researchers still working out reconstitution volumes or storage windows for either compound can find general guidance in Crown Peptides’ dosage calculation guide.

Why Identity Confirmation Matters More for Selective Peptides

Selectivity is a function of exact structure — swap even one residue and a “selective” secretagogue can stop being selective. That makes mass spectrometry identity confirmation especially important for a compound like Ipamorelin, where the entire value proposition rests on a specific amino acid substitution doing its job correctly.

Every batch of GHRP-6 and Ipamorelin that Crown Peptides ships is verified by HPLC for purity and mass spectrometry for identity, with a batch-specific Certificate of Analysis provided. Both are small, relatively stable hexapeptides, but we still recommend the same baseline handling: store lyophilised vials refrigerated or frozen, protected from light, and reconstitute only what a given research session requires.

Frequently Asked Questions

Is Ipamorelin just a “better” version of GHRP-6?

Not better — more selective for one specific purpose. GHRP-6’s broader hormonal activity is exactly what makes it useful for research into ghrelin-receptor effects beyond the GH axis, which Ipamorelin’s design deliberately minimises.

Why does GHRP-6 affect appetite and Ipamorelin does not, if they hit the same receptor?

Both bind GHS-R1a, but Ipamorelin’s structural changes appear to favour the receptor conformation linked to GH release specifically, while GHRP-6 engages a broader set of downstream effects — appetite among them — associated with the same receptor family.

Has either compound been studied in a completed human trial?

Both have been studied in controlled human research settings — the Ipamorelin selectivity data and GHRP-6/GHRH synergy work cited above both come from human studies — but neither is an approved medicine, and Crown Peptides sells both strictly as research compounds, not for human use.

Same Receptor, Different Research Tools

The GHRP-6 versus Ipamorelin comparison is a genuinely good illustration of how far peptide engineering has come since the first growth hormone secretagogues were discovered. One compound proved the mechanism worked at all; the other proved it could be refined. Both remain legitimate, well-characterised research tools — the right choice just depends on whether a broader hormonal response or a narrower one is what the study actually needs.

Crown Peptides stocks both GHRP-6 and Ipamorelin as HPLC-verified research peptides, each shipped with a batch-specific Certificate of Analysis. See the full growth-hormone secretagogue range at Crown Peptides.